TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —TraumaTone — The world's first percutaneous bioelectronic implant for PTSD —

Stimalia

TraumaTone
quieting the body's alarm system.

Incubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to ScaleIncubated by the #1 university accelerator worldwideimec.istartEndorsed by the support for tech entrepreneursIgnity Start to Scale
The unmet need001 / 005
24M
Adults affected EU + US
50%
Treatment-resistant despite standard care
$350B
Annual societal cost
Higher opioid dependency risk

PTSD is not a thought disorder. It is the body stuck in fight-or-flight.

The approach002 / 005
01 — Targeted

The source, not the symptom

Modulates the stellate ganglion. It is the sympathetic system's central relay. Decades of clinical data show 70–80% response rates.

02 — Minimally invasive

A single outpatient procedure

One percutaneous implantation. No daily pills. No repeated injections. Designed for durable, programmable benefit.

03 — Drug-free

No systemic exposure

The body's sympathetic alarm is calmed at its physiological origin, without pharmacological side effects.

Calm the alarm.
Restore the patient.

Founders003 / 005
Olivier Ménage, PharmD

Olivier Ménage, PharmD

CEO & Co-Founder

25+ years in medical devices across neuromodulation, minimally invasive surgery, and digital health. Founder of MONA.health. Former CEO at Man&Science.

Pascal Doguet, PhD

Pascal Doguet, PhD

CTO & Co-Founder

25+ years pioneering neurostimulation R&D. Co-inventor on 300+ patent claims. Co-founder and CTO at Synergia Medical.

Sylvain d'Amico, MSc

Sylvain d'Amico, MSc

CCO & Co-Founder

25+ years in neurovascular and cardiovascular innovation — Boston Scientific, Edwards Lifesciences, Stryker, Penumbra.

Today a procedure.
Tomorrow a therapy.

Research & editorials004 / 005
The Hidden Crisis in Elite Sports
Editorial · 8 min read

The Hidden Crisis in Elite Sports

One in eight elite athletes suffers from PTSD. Most will never tell you. The science now shows why. And it is not what you think.

Read more
Stellate Ganglion Block: A Paradigm Shift
Research · 10 min read

Stellate Ganglion Block: A Paradigm Shift

Why 70–80% of patients experience meaningful symptom reduction with sympathetic block. Why continuous neuromodulation extends the benefit.

Read more
PTSD in Military Populations
Editorial · 7 min read

PTSD in Military Populations

Why veterans and service members represent both the highest-need and highest-impact population for breakthrough PTSD interventions.

Read more

Restoring calm. Reclaiming lives.

Read the insights
Receive scientific updates and milestones

Stimalia

Bioelectronic medicine · Louvain La Neuve · est. 2025